Lexicon Pharmaceuticals, Inc.
LXRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001062822
No open-market purchases or sales by Lexicon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 149 institutions reported holding it in 13F filings for Q2 2026, worth $875.1M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Lexicon Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- −9 vs. Q4 2021
- Shares held
- 120.2M
- −1.37M (−1.1%) vs. Q4 2021
- Total value
- $251.3M
- −$227.6M (−47.5%) vs. Q4 2021
- New holders
- 7
- 33 more added
- Sold out
- 16
- 39 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LXRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 149 | $875.1M |
| Q1 2026 | 137 | $504.5M |
| Q4 2025 | 126 | $299.5M |
| Q3 2025 | 124 | $344.4M |
| Q2 2025 | 123 | $242.9M |
| Q1 2025 | 127 | $122.5M |
| Q4 2024 | 127 | $220.1M |
| Q3 2024 | 137 | $453.1M |
| Q2 2024 | 127 | $471.0M |
| Q1 2024 | 118 | $417.8M |
| Q4 2023 | 106 | $279.8M |
| Q3 2023 | 112 | $205.8M |
| Q2 2023 | 123 | $438.2M |
| Q1 2023 | 104 | $353.8M |
| Q4 2022 | 105 | $280.5M |
| Q3 2022 | 98 | $357.3M |
| Q2 2022 | 86 | $221.0M |
| Q1 2022 | 101 | $251.3M |
| Q4 2021 | 110 | $478.9M |
| Q3 2021 | 96 | $583.0M |
| Q2 2021 | 107 | $540.2M |
| Q1 2021 | 107 | $711.5M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Lexicon Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Artal Group S.A. | 71,178,364 | $148.8M | 6.29% | 00.0% | Unchanged |
| Eversept Partners, LP | 0 | $0 | 0.00% | −797,694−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −135,500−100.0% | Sold out |
| Natixis Advisors, L.P. | 0 | $0 | 0.00% | −93,969−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −73,000−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −38,700−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −25,604−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −20,131−100.0% | Sold out |
| Schechter Investment Advisors, LLC | 0 | $0 | 0.00% | −14,217−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −13,429−100.0% | Sold out |
| Adviser Investments LLC | 0 | $0 | 0.00% | −13,289−100.0% | Sold out |
| Campbell & CO Investment Adviser LLC | 0 | $0 | 0.00% | −11,900−100.0% | Sold out |
| Equitable Holdings, Inc. | 0 | $0 | 0.00% | −11,340−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −10,688−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −991−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −1−100.0% | Sold out |